General Content

Referenced publications

  1. Morgan-Capner, P. Laboratory diagnosis of rubella. Summary of recommendations of PHLS Working Party. PHLS Microbiol Dig 1988; 5: 49- 52.
  2. Crowcroft N S, Roth C E, Cohen B J, Miller E. Guidance for control of parvovirus B19 infection in healthcare settings and the community. J Publ Hlth Med 1999; 21: 439-446.
  3. Nathwani D, Maclean A, Conway S, Carrington D. Varicella infection in pregnancy and the newborn. J Infect 1998; 36 Suppl 1: 59-71.
  4. Salisbury D M, Begg T M, eds. Immunisation against infectious disease (The Green Book). London: HMSO, 1996.
  5. Miller E, Cradock-Watson J E, Pollock T M. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982; ii: 781-4.
  6. Anderson M J, Kidd J M, Morgan-Capner P. Human parvovirus and rubella like illness. Lancet 1985; ii: 663.
  7. Enders G, Nickerl-Pacher U, Miller E, Cradock-Watson J E. Outcome of confirmed periconceptional maternal rubella. Lancet 1988; i: 1445-7.
  8. Grillner L, Forsgren M, Barr B, et al. Outcome of rubella during pregnancy with special references to the 17 th -24 th weeks of gestation. Scand J Infect Dis 1983; 15: 321-5.
  9. Best J M, Banatvala J E, Morgan-Capner P, Miller E. Fetal infection after maternal re-infection with rubella: criteria for defining re-infection. BMJ 1989; 299: 773-5.
  10. Morgan-Capner P, Miller E, Vurdien J E, Ramsay M E B. Outcome of pregnancy after maternal re-infection with rubella. Commun Dis Rep Rev 1991; 1: R57-9.
  11. Miller E, Waight P, Gay N, et al. The epidemiology of rubella in England and Wales before and after the 1994 measles-rubella immunisation campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Commun Dis Rep Rev 1997; 4: R26-32.
  12. Tookey P A, Peckham C S. Surveillance of congenital rubella in Great Britain, 1971-96. BMJ 1999; 318: 769-70.
  13. Tookey P, Molyneux P, Helms P. UK case of congenital rubella can be linked to Greek cases. BMJ 2000: 321: 766-7.
  14. Pattison J R. Human parvoviruses. In: Principles and practice of clinical virology, 4 th edn, Zuckerman A J, Banatvala J E, Pattison J R, eds. Chichester: John Wiley, 2000.
  15. Miller E, Fairley C K, Cohen B J, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Brit J Obs Gynae 1998; 105: 174-8.
  16. Donders G G G, van Lierde S, van Elsacker-Niele A-M W, et al. Survival after intrauterine parvovirus B19 infection with persistence in early infancy: a two year follow up. Paediatr Infect Dis J 1994; 13: 234-6.
  17. Anderson M J, Higgins P G, Davis L R, et al. Experimental parvovirus infection in man. J Infect Dis 1985; 152: 257-265.
  18. Gay N J, Hesketh L M, Cohen B J, et al. Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy? Commun Dis Rep Rev 1994; 4, R104-7.
  19. Enders G, Miller E. Varicella and herpes zoster in pregnancy and the newborn. In: Varicella zoster virus: basic virology and clinical management. Arvin A M, Gershon A A, eds. Cambridge: Cambridge University Press, 2000. In press.
  20. Gershon A A, Steinberg S P, Gelb L. Clinical reinfection with varicella-zoster virus. J Infect Dis 1984; 149: 137-42.
  21. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Micro 1993; 4: 222-230.
  22. Gershon A A, LaRussa P, Hardy I, Steinberg S, Silverstein S. Varicella vaccine: the American experience. J Infect Dis 1991; 166(suppl 1): S63-8.
  23. Katz M. Clinical spectrum of measles and MA. Curr Topics Microbiol Immunol 1995; 191: 3-12.
  24. Eberhart-Phillips J E, Frederick P D, Baron R C, Mascola L. Measles in pregnancy: a descriptive study of 58 cases. Obstet Gynaecol 1993; 82: 797- 801.
  25. Gay N, Ramsay N, Cohen B, Hesketh L, Morgan-Capner P, Brown D, Miller E. The epidemiology of measles in England and Wales since the 1994 vaccination campaign. CDR Rev 1997; 7: R17-21.
  26. Hanratty B, Holt T, Duffell E, et al. UK measles outbreak on non-immune anthroposophic communities: the implications for the elimination of measles from Europe. Epidemiol Infect 2000; 125: 377-83.
  27. Payne D. Ireland's measles outbreak kills two. BMJ 2000; 321: 197.
  28. Basso N G, Forseca M E, Garcia A G, et al. Enterovirus isolation from fetal and placental tissues. Acta Virologica 1990; 34: 49-57.
  29. Nagington J, Gandy G, Walker J, et al. Use of normal immunoglobulin in an echovirus 11 outbreak in a special-care baby unit. Lancet 1983; ii: 443-6.
  30. Schooley R T. Epstein-Barr virus (infectious mononucleosus). In: Principles and practice of infectious diseases, 5 th edn. Mandell G C, Bennett J E, Dolin R, eds. London: Churchill Livingstone, 2000.
  31. Arvin A M, Maldonado Y A. Other viral infections of the fetus and newborn. In: Infectious diseases of the fetus and newborn infect, 4 th edn. Remington JS, Klein J O, eds. Philadelphia: W B Saunders, 1995.
  32. Boppana S B, Pass R F, Britt W J, Stagno S, Alford C A. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 1992; 11: 93-9.
  33. Fairley C K, Smoleniec J S, Caul O E, Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995; 346: 1335-7.
  34. Centers for Disease Control. Measles prevention: recommendations of the Immunization Practices Advisory Committee. MMWR 1989; 38: SU09.
  35. Thomas J I J, Morgan-Capner P, Enders G, et al. Persistence of specific IgM and low avidity specific IgG following primary rubella. J Virol Meth 1992; 39: 149-55.
  36. Skendzel L P. Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 1996; 106: 170-74.
  37. Wallace M R, Bowler W A, Murray N B, Brodine S K, Oldfield E C. Treatment of adult varicella with oral acyclovir. Ann Intern Med 1992: 117: 358-63.

 

 

 

 


Last reviewed: 10 April 2008